메뉴 건너뛰기




Volumn 9, Issue 6, 2010, Pages 1820-1830

Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

EID: 77953433898     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0249     Document Type: Article
Times cited : (34)

References (43)
  • 1
    • 45949104460 scopus 로고    scopus 로고
    • New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents
    • Dinh P, Harriett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hemat 2008;67:103-12.
    • (2008) Crit Rev Oncol Hemat , vol.67 , pp. 103-112
    • Dinh, P.1    Harriett, P.2    Piccart-Gebhart, M.J.3    Awada, A.4
  • 3
    • 0036024584 scopus 로고    scopus 로고
    • Ovarian cancer: Progress and continuing controversies in management
    • Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002;38:1701-7.
    • (2002) Eur J Cancer , vol.38 , pp. 1701-1707
    • Moss, C.1    Kaye, S.B.2
  • 4
    • 0036711606 scopus 로고    scopus 로고
    • Part I: Chemotherapy for epithelial ovarian cancer - Treatment at first diagnosis
    • Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. Lancet Oncol 2002;3:529-36.
    • (2002) Lancet Oncol , vol.3 , pp. 529-536
    • Harries, M.1    Gore, M.2
  • 5
    • 0036089979 scopus 로고    scopus 로고
    • Docetaxel: Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model
    • DOI 10.1007/s00280-002-0439-1
    • Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002;49:499-503. (Pubitemid 34671286)
    • (2002) Cancer Chemotherapy and Pharmacology , vol.49 , Issue.6 , pp. 499-503
    • Marchettini, P.1    Stuart, O.A.2    Mohamed, F.3    Yoo, D.4    Sugarbaker, P.H.5
  • 6
    • 40749086094 scopus 로고    scopus 로고
    • Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer
    • Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer 2008;18:20-5.
    • (2008) Int J Gynecol Cancer , vol.18 , pp. 20-25
    • Howell, S.B.1
  • 9
    • 29144462090 scopus 로고    scopus 로고
    • Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
    • DOI 10.1016/j.ygyno.2005.11.013, PII S0090825805010012
    • Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intrapentoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:27-32. (Pubitemid 41815045)
    • (2006) Gynecologic Oncology , vol.100 , Issue.1 , pp. 27-32
    • Walker, J.L.1    Armstrong, D.K.2    Huang, H.Q.3    Fowler, J.4    Webster, K.5    Burger, R.A.6    Clarke-Pearson, D.7
  • 10
    • 0035214416 scopus 로고    scopus 로고
    • Metronomic scheduling: The future of chemotherapy?
    • Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40.
    • (2001) Lancet Oncol , vol.2 , pp. 733-740
    • Gasparini, G.1
  • 11
    • 41649097550 scopus 로고    scopus 로고
    • Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer
    • DOI 10.1158/1535-7163.MCT-07-2117
    • Vassileva V, Piquette-Miller M. Ovarian tumour repopulation in response to sustained and intermittent paclitaxel therapy. Clin Pharmacol Ther 2008;83:S52-S. (Pubitemid 351482145)
    • (2008) Molecular Cancer Therapeutics , vol.7 , Issue.3 , pp. 630-637
    • Vassileva, V.1    Allen, C.J.2    Piquette-Miller, M.3
  • 12
    • 33644986064 scopus 로고    scopus 로고
    • Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure?
    • Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 2006;24:1020-2.
    • (2006) J Clin Oncol , vol.24 , pp. 1020-1022
    • Brade, A.M.1    Tannock, I.F.2
  • 13
    • 57449102025 scopus 로고    scopus 로고
    • Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
    • Vassileva V, Moriyama EH, De Souza R, et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Brit J Cancer 2008; 99:2037-43.
    • (2008) Brit J Cancer , vol.99 , pp. 2037-2043
    • Vassileva, V.1    Moriyama, E.H.2    De Souza, R.3
  • 14
    • 34548563731 scopus 로고    scopus 로고
    • Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model
    • DOI 10.1007/s00280-007-0449-0
    • Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 2007;60: 907-14. (Pubitemid 47389398)
    • (2007) Cancer Chemotherapy and Pharmacology , vol.60 , Issue.6 , pp. 907-914
    • Vassileva, V.1    Grant, J.2    De Souza, R.3    Allen, C.4    Piquette-Miller, M.5
  • 15
    • 67349093532 scopus 로고    scopus 로고
    • Biocompatibility of injectable chitosan-phospholipid implant systems
    • De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials 2009;30:3818-24.
    • (2009) Biomaterials , vol.30 , pp. 3818-3824
    • De Souza, R.1    Zahedi, P.2    Allen, C.J.3    Piquette-Miller, M.4
  • 16
    • 67649664258 scopus 로고    scopus 로고
    • Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity
    • Zahedi P, De Souza R, Piquette-Miller M, Allen C. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. Int J Pharm 2009;377:76-84.
    • (2009) Int J Pharm , vol.377 , pp. 76-84
    • Zahedi, P.1    De Souza, R.2    Piquette-Miller, M.3    Allen, C.4
  • 17
    • 0037331627 scopus 로고    scopus 로고
    • A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study
    • Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130-5.
    • (2003) Gynecol Oncol , vol.88 , pp. 130-135
    • Rose, P.G.1    Blessing, J.A.2    Ball, H.G.3
  • 18
    • 0028175036 scopus 로고
    • Paclitaxel (Taxol(TM) ) and docetaxel (Taxotere(TM) ): Not simply two of a kind
    • Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol(Tm)) and docetaxel (Taxotere(Tm)) - not simply 2 of a kind. Ann Oncol 1994;5:495-505. (Pubitemid 2112632)
    • (1994) Annals of Oncology , vol.5 , Issue.6 , pp. 495-505
    • Verweij, J.1    Clavel, M.2    Chevalier, B.3
  • 20
    • 0028356485 scopus 로고
    • Comparison of paclitaxel and docetaxel activity on human ovarian-carcinoma xenografts
    • Nicoletti MI, Lucchini V, Dincalci M, Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian-carcinoma xenografts. Eur J Cancer 1994;30A:691-6.
    • (1994) Eur J Cancer , vol.30 A , pp. 691-696
    • Nicoletti, M.I.1    Lucchini, V.2    Dincalci, M.3    Giavazzi, R.4
  • 21
    • 38649114430 scopus 로고    scopus 로고
    • Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer
    • Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol 2008;108:385-94.
    • (2008) Gynecol Oncol , vol.108 , pp. 385-394
    • Greenaway, J.1    Moorehead, R.2    Shaw, P.3    Petrik, J.4
  • 22
    • 0033014481 scopus 로고    scopus 로고
    • Body condition scoring: A rapid and accurate method for assessing health status in mice
    • Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 1999;49:319-23.
    • (1999) Lab Anim Sci , vol.49 , pp. 319-323
    • Ullman-Culleré, M.H.1    Foltz, C.J.2
  • 23
    • 33846441659 scopus 로고    scopus 로고
    • Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    • Kamat AA, Kim TJ, Landen CN, Jr., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8.
    • (2007) Cancer Res , vol.67 , pp. 281-288
    • Kamat, A.A.1    Kim, T.J.2    Landen Jr., C.N.3
  • 24
    • 0347364775 scopus 로고    scopus 로고
    • Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics
    • Morgan RJ, Jr., Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003;9:5896-901.
    • (2003) Clin Cancer Res , vol.9 , pp. 5896-5901
    • Morgan Jr., R.J.1    Doroshow, J.H.2    Synold, T.3
  • 25
    • 70349668946 scopus 로고    scopus 로고
    • The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
    • Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23.
    • (2009) J Clin Invest , vol.119 , pp. 3011-3023
    • Charles, K.A.1    Kulbe, H.2    Soper, R.3
  • 26
    • 0037314551 scopus 로고    scopus 로고
    • Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts
    • Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EAG. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003;199:221-8.
    • (2003) J Pathol , vol.199 , pp. 221-228
    • Duan, W.R.1    Garner, D.S.2    Williams, S.D.3    Funckes-Shippy, C.L.4    Spath, I.S.5    Blomme, E.A.G.6
  • 27
    • 28244480457 scopus 로고    scopus 로고
    • Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis
    • Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005;167:1739-52.
    • (2005) Am J Pathol , vol.167 , pp. 1739-1752
    • Said, N.1    Motamed, K.2
  • 28
    • 34248190133 scopus 로고    scopus 로고
    • Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study
    • Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40.
    • (2007) J Urol , vol.177 , pp. 2136-2140
    • Lord, R.1    Nair, S.2    Schache, A.3
  • 29
    • 0037093209 scopus 로고    scopus 로고
    • Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
    • Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
    • (2002) Cancer Res , vol.62 , pp. 2731-2735
    • Man, S.1    Bocci, G.2    Francia, G.3
  • 30
    • 0035887463 scopus 로고    scopus 로고
    • Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
    • Bello LS, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
    • (2001) Cancer Res , vol.61 , pp. 7501-7506
    • Bello, L.S.1    Carrabba, G.2    Giussani, C.3
  • 31
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
    • (2004) Nat Rev Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 32
    • 0031719516 scopus 로고    scopus 로고
    • Role of vascular endothelial growth factor in ovarian cancer - Inhibition of ascites formation by immunoneutralization
    • Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer - inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.
    • (1998) Am J Pathol , vol.153 , pp. 1249-1256
    • Mesiano, S.1    Ferrara, N.2    Jaffe, R.B.3
  • 33
    • 65649100065 scopus 로고    scopus 로고
    • Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: HnRNP K as a player
    • Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 2009;124:2989-96.
    • (2009) Int J Cancer , vol.124 , pp. 2989-2996
    • Benelli, R.1    Monteghirfo, S.2    Balbi, C.3    Barboro, P.4    Ferrari, N.5
  • 34
    • 0037268220 scopus 로고    scopus 로고
    • Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
    • Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anti-Cancer Drug 2003;4:13-9.
    • (2003) Anti-Cancer Drug , vol.4 , pp. 13-19
    • Wang, J.1    Lou, P.2    Lesniewski, R.3    Henkin, J.4
  • 35
    • 0842282637 scopus 로고    scopus 로고
    • Taxane-mediated antiangiogenesis in vitro: Influence of formulation vehicles and binding proteins
    • Ng SSW, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004;64:821-4.
    • (2004) Cancer Res , vol.64 , pp. 821-824
    • Ng, S.S.W.1    Figg, W.D.2    Sparreboom, A.3
  • 36
  • 38
    • 34548463397 scopus 로고    scopus 로고
    • Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers
    • Hughes J, Gobe G. Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology 2007;12:452-8.
    • (2007) Nephrology , vol.12 , pp. 452-458
    • Hughes, J.1    Gobe, G.2
  • 39
    • 0033600733 scopus 로고    scopus 로고
    • The mode of action of Taxol: Apoptosis at low concentration and necrosis at high concentration
    • Yeung TK, Germond C, Chen X, Wang Z. The mode of action of Taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999;263:398-404.
    • (1999) Biochem Biophys Res Commun , vol.263 , pp. 398-404
    • Yeung, T.K.1    Germond, C.2    Chen, X.3    Wang, Z.4
  • 40
    • 60649100252 scopus 로고    scopus 로고
    • Cancer stem cells and tumor response to therapy: Current problems and future prospects
    • Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009;19:96-105.
    • (2009) Semin Radiat Oncol , vol.19 , pp. 96-105
    • Milas, L.1    Hittelman, W.N.2
  • 41
    • 0030739859 scopus 로고    scopus 로고
    • A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
    • Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
    • (1997) Radiother Oncol , vol.44 , pp. 123-136
    • Dische, S.1    Saunders, M.2    Barrett, A.3    Harvey, A.4    Gibson, D.5    Parmar, M.6
  • 42
    • 0344738570 scopus 로고    scopus 로고
    • Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: Pilot study
    • Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytom Part A 2003;51A:1-6.
    • (2003) Cytom Part A , vol.51 , pp. 1-6
    • Davis, A.J.1    Chapman, W.2    Hedley, D.W.3    Oza, A.M.4    Tannock, I.F.5
  • 43
    • 0032930199 scopus 로고    scopus 로고
    • Paclitaxel (taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
    • Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-6.
    • (1999) Cancer Biother Radiopharm , vol.14 , pp. 31-36
    • Lau, D.H.1    Xue, L.2    Young, L.J.3    Burke, P.A.4    Cheung, A.T.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.